T1 mapping shows promise for assessing neuroblastoma
The common MRI technique called T1 mapping -- typically used for patients with...Read more on AuntMinnie.comRelated Reading: Imaging shows new, post-SARS-CoV-2 illness in children Preop MRI finds 11% more cancer in women with DCIS PET, MRI uncover women's predisposition to Alzheimer's Imaging reveals baby girl in SC born with 2nd mouth Caution indicated with new GBCAs for kidney patients (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 1, 2020 Category: Radiology Source Type: news

Preop MRI finds 11% more cancer in women with DCIS
Preoperative breast MRI finds 11% more cancer in women with ductal carcinoma...Read more on AuntMinnie.comRelated Reading: Years later, DCIS tied to more imaging but not anxiety Who gets breast cancer treatment during a pandemic? Breast MRI works as presurgical tool 10-minute breast MRI scan beats DBT for invasive cancer Does imaging modality influence DCIS recurrence? (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 24, 2020 Category: Radiology Source Type: news

Increased Risk for Invasive Breast Cancer After DCIS Increased Risk for Invasive Breast Cancer After DCIS
A new analysis shows that any diagnosis of ductal carcinoma in situ is associated with a long-term risk of invasive breast cancer and that treatment lowers this risk.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 4, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Very Early-Stage Breast Cancer Ups Long-Term Odds for Invasive Tumors: Study
FRIDAY, May 29, 2020 -- Women with cancerous cells in their milk ducts -- also known as DCIS -- are at a high risk for developing fatal breast cancer, British researchers report. DCIS is short for ductal carcinoma in situ, an early form of breast... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 29, 2020 Category: General Medicine Source Type: news

Trastuzumab achieves slight reduction in recurrence for women with HER2-positive DCIS
(NRG Oncology) The addition of the monoclonal antibody therapy Trastuzumab to radiotherapy did not reach the protocol objective of a 36% reduction in the ipsilateral breast tumor recurrence rate for women with HER2-positive ductal carcinoma in situ (DCIS) on the NRG Oncology clinical trial NSABP B-43. The trial did find a statistically non-significant, modest (19%) reduction in the rate of recurrence among women that received trastuzumab, but this difference was not statistically significant. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 29, 2020 Category: Cancer & Oncology Source Type: news

Risk for Later Invasive Breast Cancer Up for Women With DCIS
Risks for invasive breast cancer, death from breast cancer higher for up to 20 years following diagnosis (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 28, 2020 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Radiology, Surgery, Journal, Source Type: news

Risk for Later Invasive Breast Cancer Up for Women With DCIS
THURSDAY, May 28, 2020 -- Women with screening-detected ductal carcinoma in situ (DCIS) have increased long-term risks for invasive breast cancer and breast cancer death, according to a study published online May 27 in The BMJ. Gurdeep S. Mannu,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 28, 2020 Category: Pharmaceuticals Source Type: news

Years later, DCIS tied to more imaging but not anxiety
In the five years after treatment, women with a history of ductal carcinoma...Read more on AuntMinnie.comRelated Reading: Who gets breast cancer treatment during a pandemic? Sentinel lymph node biopsy unnecessary for DCIS Does imaging modality influence DCIS recurrence? Preop breast MRI improves DCIS surgical planning (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - May 26, 2020 Category: Radiology Source Type: news

How to Think About Your Cancer Care in the Time of COVID-19
Getting the news that you have cancer is overwhelming and frightening. The COVID-19 crisis adds another layer of anxiety. But know this: you can protect yourself from COVID-19 without compromising your cancer treatment. Don’t panic. In the vast majority of cases, a diagnosis of cancer is not an emergency even though it feels like one. There is time to learn about your options and sort out what is right for you. For now, there will be changes to how we do things. Some of the changes will feel disruptive, but many will lead to better, more patient-centered care. Minimizing your chances of exposure to the virus doesn&rs...
Source: TIME: Health - April 28, 2020 Category: Consumer Health News Authors: Dr. Laura Esserman Tags: Uncategorized COVID-19 Source Type: news

' Encouraging' Results With Pre-Op Therapy for DCIS'Encouraging' Results With Pre-Op Therapy for DCIS
There ' s a template now for treating DCIS with pre-operative endocrine therapy, and it shows that 15% of patients have a pathologic complete response.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 17, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Sporadic activation of an oxidative stress-dependent NRF2-p53 signaling network in breast epithelial spheroids and premalignancies
Breast and mammary epithelial cells experience different local environments during tissue development and tumorigenesis. Microenvironmental heterogeneity gives rise to distinct cell regulatory states whose identity and importance are just beginning to be appreciated. Cellular states diversify when clonal three-dimensional (3D) spheroids are cultured in basement membrane, and one such state is associated with stress tolerance and poor response to anticancer therapeutics. Here, we found that this state was jointly coordinated by the NRF2 and p53 pathways, which were costabilized by spontaneous oxidative stress within 3D cult...
Source: Signal Transduction Knowledge Environment - April 13, 2020 Category: Science Authors: Pereira, E. J., Burns, J. S., Lee, C. Y., Marohl, T., Calderon, D., Wang, L., Atkins, K. A., Wang, C.-C., Janes, K. A. Tags: STKE Research Articles Source Type: news

PreludeDx Announces New Response Type Biosignature Data at the 37th Annual Miami Breast Cancer Conference
New Response Type™ Biosignature Identifies Women at Elevated Risk of Recurrence after Surgery and Radiation Therapy for DCIS DCISionRT integration into decision-making changed treatment recommendations in 45% of women with DCIS Prospective Trial near... Diagnostics, Oncology PreludeDx, DCISionRT, ductal carcinoma, breast cancer, DCIS (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 6, 2020 Category: Pharmaceuticals Source Type: news

Digital mammo for microcalcifications: A mixed bag?
The performance of full-field digital mammography (FFDM) compared with film-screen...Read more on AuntMinnie.comRelated Reading: AI performs well in large-scale breast screening study Doubts persist over DBT's clinical impact Does imaging modality influence DCIS recurrence? SWE identifies malignant breast microcalcifications ABUS better than DBT for diagnostic workup (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - February 4, 2020 Category: Radiology Source Type: news

RT for DCIS Ups Mortality Risk in Invasive Second Breast Cancer
Rates of mortality for invasive second breast cancer higher in those with prior radiotherapy for DCIS (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 20, 2019 Category: Cancer & Oncology Tags: Gynecology, Oncology, Radiology, Journal, Source Type: news

RT for DCIS Ups Mortality Risk in Invasive Second Breast Cancer
FRIDAY, Dec. 20, 2019 -- For women with primary ductal carcinoma in situ (DCIS), use of radiotherapy (RT) is associated with increased rates of breast cancer-specific mortality for those women who subsequently develop an invasive second breast... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 20, 2019 Category: Pharmaceuticals Source Type: news